Initiation of Phase I clinical study of first needle-free COVID-19 vaccine

Vaxxas, a clinical-stage biotechnology company commercialising a novel vaccination platform, today announced the initiation of a Phase I clinical trial with the first needle-free COVID-19 vaccine candidate delivered using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology.

Read the full story via Vaxxas